Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-23T21:16:49.489Z Has data issue: false hasContentIssue false
  • English
  • Français

Mixed Amphetamine Salts Extended-Release in the Treatment of Adult ADHD: A Randomized, Controlled Trial

Published online by Cambridge University Press:  07 November 2014

Richard H. Weisler ,
Joseph Biederman ,
Thomas J. Spencer ,
Timothy E. Wilens ,
Stephen V. Faraone ,
Allan K. Chrisman ,
Stephanie C. Read  and
Simon J. Tulloch
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a serious neurobehavioral disorder of childhood onset that often persists into adolescence and adulthood. Functional impairments, underachievement, and difficult interpersonal relationships illustrate the need for effective treatment of ADHD through adulthood.

Method: This prospective, multisite, randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study was conducted to assess the efficacy, safety, and duration of action of mixed amphetamine salts extended-release (MAS XR) in adults with ADHD, combined type. Adults ≥ 18 years of age were given placebo or MAS XR 20, 40, or 60 mg/day for 4 weeks. The main outcome measures were the ADHD Rating Scale and Conners' Adult ADHD Rating Scale Short Version Self-Report (CAARS-S-S).

Results: Two hundred fifty-five subjects were randomly assigned to treatment with MAS XR or placebo. MAS XR treatment was associated with statistically and clinically significant ADHD symptom reduction at endpoint; mean ADHD Rating Scale scores were 18.5 for the 20-mg group (P=.001), 18.4 for the 40-mg group (P<.001), and 18.5 for the 60-mg group (P<.001). Adults with severe symptoms (ADHD Rating Scale score ≥32 at baseline) had significantly greater symptom reduction with the highest MAS XR dose (60 mg/day), however, this dose-response relationship was determined by post-hoc analysis. The mean MAS XR effect size was 0.8. Statistically significant (P<.05) improvements in CAARS-S-S ADHD index scores occurred at 4- and 12-hours postdose for all MAS XR groups, indicating a 12-hour duration of effect. Symptoms improved within the first treatment week. Most adverse events reported were mild or moderate in intensity, arid the most commonly reported adverse events were consistent with the known profile of stimulant medications. Vital signs and electrocardiograms showed no clinically significant cardiovascular changes.

Conclusion: These results suggest that MAS XR is safe and effective in adults with ADHD and controlled ADHD symptoms for up to 12 hours.

Type
Original Research
Information
CNS Spectrums , Volume 11 , Issue 8 , August 2006 , pp. 625 - 639
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Barkley, RA. Developmental course, adult outcome, and clinic-referred ADHD adults. In: Barkley, RA, ed. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York, NY: Guilford Press; 1998:186–224.Google Scholar
2.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
3.Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics. 2000;105:1158–1170.Google Scholar
4.Rowland, AS, Umbach, DM, Stallone, L, Naftel, J, Bohlig, M, Sandler, DP. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health. 2002;92:231–234.Google Scholar
5.Faraone, SV, Sergeant, J, Gillberg, C, Biederman, J. The Worldwide Prevalence of ADHD: Is it an American Condition? World Psychiatry. 2003;2:104–113.Google ScholarPubMed
6.Kessler, RC, Adler, L, Barkley, R, et al.The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716–723.CrossRefGoogle ScholarPubMed
7. US Census Bureau Web site. DP-1: Profile of General Demographic Characteristics: 2000. Data set: Census 2000 Summary File 1 (SF 1). Available at: http://factfinder.census.gov/servlet/QTTable?_bm=n&_lang=en&qr_name=DEC_2000_SF1_U_DP1&ds_name=DEC_2000_SF1_U&geo_id=01000US. Accessed September 18, 2005.Google Scholar
8.Faraone, SV, Spencer, TJ, Montano, B, Biederman, J. Attention-deficit/hyperactivity disorder in adults. A survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164:1221–1226.CrossRefGoogle ScholarPubMed
9.Faraone, SV, Biederman, J, Spencer, T, et al.Attention-deficit/hyperactivity in adults: an overview. Biol Psychiatry. 2000;48:9–20.CrossRefGoogle ScholarPubMed
10.Hale, TS, Hariri, AR, McCracken, JT. Attention-deficit/hyperactivity disorder: perspectives from neuroimaging. Ment Retard Dev Disabil Res Rev. 2000;6:214–219.Google Scholar
11.Kaplan, RF, Stevens, M. A review of adult ADHD: a neuropsychological and neuroimaging perspective. CNS Spectr. 2002;7:355–353.Google Scholar
12.Biederman, J, Mick, E, Faraone, SV. Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816–818.Google Scholar
13.Millstein, RB, Wilens, TE, Biederman, J, Spencer, TJ. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Atten Disord. 1997;2:159–166.Google Scholar
14.Weiss, G, Hechtman, L, Perlman, T, Hopkins, J, Wener, A. Hyperactives as young adults: a controlled, prospective ten-year follow-up of 75 children. Arch Gen Psychiatry. 1979;36:675–681.Google Scholar
15.Mannuzza, S, Klein, RG, Bessler, A, Malloy, P, LaPadula, M. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50:565–576.CrossRefGoogle ScholarPubMed
16.Biederman, J, Faraone, SV, Spencer, TJ, et al.Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524–540.Google Scholar
17.Barkley, RA, Guevremont, DC, Anastopoulos, AD, DuPaul, GJ, Shelton, TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics. 1993;92:212–218.Google Scholar
18.Spencer, T, Wilens, T, Biederman, J, Faraone, SV, Ablon, S, Lapey, K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434–443.Google Scholar
19.Spencer, T, Biederman, J, Wilens, T, et al.Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775–782.Google Scholar
20.Swanson, J. Compliance with stimulants for attention-deficit/hyperactivity disorder. Issues and approaches for improvement. CNS Drugs. 2003;17:117–131.CrossRefGoogle ScholarPubMed
21.Jaffe, SL. Failed attempts at intranasal abuse of Concerts [letter]. J Am Acad Child Adolesc Psychiatry. 2000;41:5.Google Scholar
Comment in: J Am Acad Child Adolesc Psychiatry. 2000;41:756.Google Scholar
22.Castaneda, R, Levy, R, Hardy, M, Trujillo, M. Long-acting stimulant for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatr Serv. 2000;51:169–171.Google Scholar
23.Tulloch, SJ, Zhang, Y, McLean, A, Wolf, KN. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22:1405–1415.Google Scholar
24.McCracken, JT, Biederman, J, Greenhill, LL, et al.Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:673–683.Google Scholar
25.Biederman, J, Lopez, FA, Boellner, SW, Chandler, MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110(2 pt 1):258–266.CrossRefGoogle ScholarPubMed
26.Clausen, SB, Read, SC, Tulloch, SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr. 2005;10(12 suppl 20):6–15.CrossRefGoogle ScholarPubMed
27.Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th ed. Rockville, MD: Department of Health and Human Services, Center for Drug Evaluation and Research, Office of Epidemiology Biostatistics; 1995.Google Scholar
28.SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.12. Cary, NC: SAS Institute; 1997.Google Scholar
29.Chobanian, AV, Bakris, GL, Black, HR, et al.Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252. Epub 2003 Dec 1.CrossRefGoogle ScholarPubMed
30.Committee for Proprietary Medicinal Products. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London, UK: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit: 1997 Dec 17. Report No.: CPMP/986/96.Google Scholar
31.Wilens, TE, Gignac, M, Swezey, Aet al.Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45:408–414.Google Scholar
32.Solanto, MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998;94:127–152.Google Scholar
33.Borcherding, BG, Keysor, CS, Cooper, TB, Rapoport, JL. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology. 1989;2:255–263.Google Scholar
34.Fischer, JF, Cho, AK. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther. 1979;192:642–653.Google Scholar
35.Faraone, SV, Spencer, T, Aleardi, M, Pagano, C, Biederman, J. Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol. 2004;54:24–29.Google Scholar
36.Wilens, TE, Haight, BR, Horrigan, JRet al.Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57:793–801.Google Scholar
37.Michelson, D, Adler, L, Spencer, T, et al.Atomoxetine in adults with ADHD: two randomized placebo-controlled studies. Biol Psychiatry. 2003;53:112–120.CrossRefGoogle ScholarPubMed
38.Spencer, T, Muniz, R, Kim, S, et al. Efficacy of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Poster presented at: annual meeting of the American Psychiatric Association: May 1-6, 2004: New York, NY.Google Scholar
39.Wilens, TE, Spencer, TJ, Biederman, J, et al.A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282–288.Google Scholar
40.Adderall, XR (package insert). Wayne, Penn: Shire US, Inc.; 2004.Google Scholar
41.Gutgesell, H, Atkins, D, Barst, R, et al.AHA Scientific Statement. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry. 1999;38:1047–1050.Google Scholar